ESMO® 2026 Highlights: Presenter Vignettes – Kohei Shitara

Dr. Kohei Shitara

Kohei Shitara

MD

National Cancer Center Hospital East

LBA79

Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): second interim analysis (IA) from HERIZON-GEA-01